Meeting its self-imposed deadline by more than a week, Cubist Pharmaceuticals Inc. submitted the new drug application for injectable Cidecin as a treatment for complicated skin and skin structure infections caused by Gram-positive organisms, including Staphylococcus aureus. (BioWorld Today)